Chakra Biotech Sdn Bhd Completes Series B Investment Round

31-Mar-2010 - Malaysia

Chakra Biotech Sdn Bhd, a Malaysian based contract research Organization (CRO), has completed a MYR18.2m Series B funding round. This brings total funding for the company to MYR20.0m. Malaysian Life Sciences Capital Fund Ltd. (MLSCF) and the Malaysian Technology Development Corporation Sdn Bhd (MTDC) participated in the round.

Chakra Biotech CEO Anthony Bishop said, "The Series B investment is a strong sign of the confidence we share with our investors that our full range of service offerings are valuable to our customers, particularly our proprietary chakragati (ckr) mouse model for screening new psychiatric drugs."

The ckr mouse model is a US Patented transgenic model of psychiatric disease.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances